Comorbid cancer is prevalent among patients with cardio-kidney-metabolic (CKM) syndrome, affecting 7.3% of the studied population and associated with worse clinical outcomes.
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, consistently improves cardiovascular, kidney, and mortality outcomes in CKM patients regardless of cancer history.
Patients with cancer history tend to have more advanced CKM stages and higher rates of adverse events, yet finerenone’s safety profile remains consistent.
This pooled analysis clarifies that cancer comorbidity does not diminish the therapeutic benefits of finerenone in a high-risk multimorbid population.
